How Peptides Are Studied

Peptide research proceeds through a sequence of methods, each narrower and more expensive than the last. Knowing what each one establishes is the difference between reading a literature and being impressed by it.

Receptor binding and cell assays

The first question is whether a molecule interacts with anything. Binding assays measure affinity for a target receptor; functional assays measure whether binding triggers a response — a second messenger, a phosphorylation event, a change in gene expression.

Establishes: that the molecule engages a target, and how strongly.

Does not establish: that engaging it produces any useful effect in a living organism. Concentrations used in cell culture are often far above anything achievable in a body, and a dish has no liver, no kidneys and no immune system.

Gene and protein expression profiling

Broader methods measure what a compound does to the transcriptome or proteome of a cell.

These produce striking numbers. The most-cited GHK-Cu work reports modulation of a very large fraction of human genes. That is genuinely interesting and it is also the kind of result that is easy to over-read: gene expression change is upstream of everything and specific to nothing.

Animal models

An injury or disease is created in an animal, the compound is administered, and an outcome is measured — histology, functional recovery, biochemical markers.

Establishes: that the compound produces an effect in a living system with intact physiology.

Does not establish: that it does so in humans. This is the step where most candidate drugs fail, and it fails for structural reasons: induced injuries in young healthy inbred rodents are not the same as spontaneous disease in heterogeneous humans with comorbidities.

Pharmacokinetics and pharmacodynamics

PK asks what the body does to the compound: absorption, distribution, metabolism, excretion, half-life. PD asks what the compound does to the body: the relationship between concentration and effect.

This work is the bridge between preclinical and clinical research. Without it there is no rational basis for choosing a dose, a route or a schedule.

It is also the step most conspicuously missing for research-chemical peptides. For compounds such as MOTS-c, no published human pharmacokinetic study exists — which means every dosing figure circulating for them is an assertion without a measurement behind it.

Human trials

Covered in detail in how FDA drug approval works. Briefly: Phase 1 for safety and PK, Phase 2 for signal and dose, Phase 3 for efficacy against clinical endpoints in a population large enough to be confident.

Systematic reviews and meta-analysis

When enough trials exist, they can be pooled. A well-conducted systematic review is the strongest form of evidence available — and it depends entirely on the quality of what goes into it.

For most peptides discussed outside clinical medicine, no meta-analysis is possible, because there are not enough trials to pool.

The question worth asking

Given any peptide, the single most informative question is: where in this sequence did the work stop, and why?

A compound with binding data and animal studies but no pharmacokinetics has not been taken seriously as a drug candidate. A compound with Phase 1 data and nothing after it either failed, or was abandoned for reasons nobody published. A compound with completed Phase 3 trials and a label has been through the whole sequence.

Every profile on this site answers that question in its Research status field, using the evidence taxonomy applied consistently across the library.